scholarly article | Q13442814 |
P50 | author | Barbara Phillips-Bute | Q115549094 |
P2093 | author name string | Grace M Lee | |
Thomas L Ortel | |||
Gowthami M Arepally | |||
Ian J Welsby | |||
P2860 | cites work | Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. | Q33328813 |
Impact of the patient population on the risk for heparin-induced thrombocytopenia. | Q33333799 | ||
Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia | Q33348070 | ||
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia | Q33364229 | ||
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? | Q33369345 | ||
Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery | Q33385134 | ||
Heparin modifies the immunogenicity of positively charged proteins | Q33391937 | ||
Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis | Q33405333 | ||
Protamine-induced immune thrombocytopenia. | Q33405699 | ||
Incidence of antibodies to protamine sulfate/heparin complexes incardiac surgery patients and impact on platelet activation and clinical outcome | Q33407438 | ||
Heparin-induced thrombocytopenia: laboratory studies | Q33451630 | ||
Protamine-induced thrombocytopenia and leukopenia | Q33457599 | ||
Protamine: a review of its toxicity | Q33457774 | ||
Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery | Q33498612 | ||
Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium | Q33500888 | ||
High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery | Q33503096 | ||
Allergy to protamine sulfate | Q33783816 | ||
Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery | Q34389614 | ||
Serious adverse reactions to protamine sulfate: are alternatives needed? | Q34557419 | ||
Allergy to protamine | Q36934496 | ||
Sperm autoantibodies as a consequence of vasectomy. II. Long-term follow-up studies | Q41156011 | ||
Risk stratification of in-hospital mortality for coronary artery bypass graft surgery | Q42679650 | ||
Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass | Q49116578 | ||
Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. | Q52996866 | ||
Protamine-induced circulatory changes. | Q54474911 | ||
Caveats for the use of surface-adsorbed protein antigen to test the specificity of antibodies | Q67486376 | ||
Adverse reactions to protamine sulfate during cardiac surgery in diabetic and non-diabetic patients | Q67945798 | ||
Frequency and specificity of protamine antibodies in diabetic and control subjects | Q68149024 | ||
A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery | Q68502476 | ||
Protamine antibody production in diabetic subjects treated with NPH insulin | Q68779348 | ||
Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine | Q69490665 | ||
High-titer protamine-specific IgG antibody associated with anaphylaxis: report of a case and quantitative analysis of antibody in vasectomized men | Q70574814 | ||
Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization | Q70641963 | ||
Interaction of Cls̄ and Cl inactivator in the presence of heparin, dextran sulfate and protamine sulfate | Q72617351 | ||
Histamine release from rat mast cells induced by protamine sulfate and polyethylene imine | Q72637925 | ||
Complement activation by heparin-protamine complexes during cardiopulmonary bypass: effect of C4A null allele | Q73716394 | ||
Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass | Q77700079 | ||
P433 | issue | 15 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2828-2835 | |
P577 | publication date | 2013-02-19 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass | |
P478 | volume | 121 |